skip to main content
OSTI.GOV title logo U.S. Department of Energy
Office of Scientific and Technical Information

Title: Uterine Artery Embolization to Treat Uterine Adenomyosis with or without Uterine Leiomyomata: Results of Symptom Control and Health-Related Quality of Life 40 Months after Treatment

Abstract

Purpose: To evaluate the clinical outcome for uterine adenomyosis with or without uterine leiomyomata 40 months after uterine artery embolization (UAE). Methods: Forty women aged 39-56 years (median 46 years) with symptomatic uterine adenomyosis and magnetic resonance imaging findings of uterine adenomyosis with or without combined uterine leiomyomata underwent UAE. Self-perceived changes in clinical symptoms were assessed, and residual symptom severity and health-related quality of life (HRQOL) after UAE were evaluated. Clinical failure was defined as no symptomatic improvement or second invasive therapy after UAE. Results were stratified by the extent of uterine adenomyosis at baseline magnetic resonance imaging. Results: Patients were followed for a median of 40 months (range 5-102 months). UAE led to symptomatic control after UAE in 29 (72.5%) of 40 patients while 11 women underwent hysterectomy (n = 10) or dilatation and curettage (n = 1) for therapy failure. No significant difference between women with pure uterine adenoymosis and women with uterine adenomyosis combined with uterine leiomyomata was observed. Best results were shown for UAE in uterine adenomyosis with uterine leiomyomata predominance as opposed to predominant uterine adenomyosis with minor fibroid disease (clinical failure 0% vs. 31.5%, P = 0.058). Throughout the study group, HRQOL scoremore » values increased and symptom severity scores decreased after UAE. Least improvement was noted for women with pure adenomyosis. Conclusions: UAE is clinically effective in the long term in most women with uterine adenomyosis. Symptomatic control and HRQOL were highest in patients with combined disease of uterine adenomyosis but leiomyomata predominance.« less

Authors:
; ; ;  [1]
  1. Charite-Universitaetsmedizin Berlin, Department of Radiology (Germany)
Publication Date:
OSTI Identifier:
21608514
Resource Type:
Journal Article
Journal Name:
Cardiovascular and Interventional Radiology
Additional Journal Information:
Journal Volume: 35; Journal Issue: 3; Other Information: DOI: 10.1007/s00270-011-0254-3; Copyright (c) 2012 Springer Science+Business Media, LLC and the Cardiovascular and Interventional Radiological Society of Europe (CIRSE); Country of input: International Atomic Energy Agency (IAEA); Journal ID: ISSN 0174-1551
Country of Publication:
United States
Language:
English
Subject:
62 RADIOLOGY AND NUCLEAR MEDICINE; ARTERIES; CONTROL; DISEASES; ELDERLY PEOPLE; NMR IMAGING; PATIENTS; STANDARD OF LIVING; SYMPTOMS; THERAPY; WOMEN; ADULTS; AGE GROUPS; AGED ADULTS; ANIMALS; BLOOD VESSELS; BODY; CARDIOVASCULAR SYSTEM; DIAGNOSTIC TECHNIQUES; FEMALES; HUMAN POPULATIONS; MAMMALS; MAN; MEDICINE; MINORITY GROUPS; ORGANS; POPULATIONS; PRIMATES; VERTEBRATES

Citation Formats

Froeling, V., E-mail: Vera.Froeling@charite.de, Scheurig-Muenkler, C., E-mail: Christian.Scheurig@charite.de, Hamm, B., E-mail: Bernd.Hamm@charite.de, and Kroencke, T. J., E-mail: thomas.kroencke@charite.de. Uterine Artery Embolization to Treat Uterine Adenomyosis with or without Uterine Leiomyomata: Results of Symptom Control and Health-Related Quality of Life 40 Months after Treatment. United States: N. p., 2012. Web. doi:10.1007/S00270-011-0254-3.
Froeling, V., E-mail: Vera.Froeling@charite.de, Scheurig-Muenkler, C., E-mail: Christian.Scheurig@charite.de, Hamm, B., E-mail: Bernd.Hamm@charite.de, & Kroencke, T. J., E-mail: thomas.kroencke@charite.de. Uterine Artery Embolization to Treat Uterine Adenomyosis with or without Uterine Leiomyomata: Results of Symptom Control and Health-Related Quality of Life 40 Months after Treatment. United States. doi:10.1007/S00270-011-0254-3.
Froeling, V., E-mail: Vera.Froeling@charite.de, Scheurig-Muenkler, C., E-mail: Christian.Scheurig@charite.de, Hamm, B., E-mail: Bernd.Hamm@charite.de, and Kroencke, T. J., E-mail: thomas.kroencke@charite.de. Fri . "Uterine Artery Embolization to Treat Uterine Adenomyosis with or without Uterine Leiomyomata: Results of Symptom Control and Health-Related Quality of Life 40 Months after Treatment". United States. doi:10.1007/S00270-011-0254-3.
@article{osti_21608514,
title = {Uterine Artery Embolization to Treat Uterine Adenomyosis with or without Uterine Leiomyomata: Results of Symptom Control and Health-Related Quality of Life 40 Months after Treatment},
author = {Froeling, V., E-mail: Vera.Froeling@charite.de and Scheurig-Muenkler, C., E-mail: Christian.Scheurig@charite.de and Hamm, B., E-mail: Bernd.Hamm@charite.de and Kroencke, T. J., E-mail: thomas.kroencke@charite.de},
abstractNote = {Purpose: To evaluate the clinical outcome for uterine adenomyosis with or without uterine leiomyomata 40 months after uterine artery embolization (UAE). Methods: Forty women aged 39-56 years (median 46 years) with symptomatic uterine adenomyosis and magnetic resonance imaging findings of uterine adenomyosis with or without combined uterine leiomyomata underwent UAE. Self-perceived changes in clinical symptoms were assessed, and residual symptom severity and health-related quality of life (HRQOL) after UAE were evaluated. Clinical failure was defined as no symptomatic improvement or second invasive therapy after UAE. Results were stratified by the extent of uterine adenomyosis at baseline magnetic resonance imaging. Results: Patients were followed for a median of 40 months (range 5-102 months). UAE led to symptomatic control after UAE in 29 (72.5%) of 40 patients while 11 women underwent hysterectomy (n = 10) or dilatation and curettage (n = 1) for therapy failure. No significant difference between women with pure uterine adenoymosis and women with uterine adenomyosis combined with uterine leiomyomata was observed. Best results were shown for UAE in uterine adenomyosis with uterine leiomyomata predominance as opposed to predominant uterine adenomyosis with minor fibroid disease (clinical failure 0% vs. 31.5%, P = 0.058). Throughout the study group, HRQOL score values increased and symptom severity scores decreased after UAE. Least improvement was noted for women with pure adenomyosis. Conclusions: UAE is clinically effective in the long term in most women with uterine adenomyosis. Symptomatic control and HRQOL were highest in patients with combined disease of uterine adenomyosis but leiomyomata predominance.},
doi = {10.1007/S00270-011-0254-3},
journal = {Cardiovascular and Interventional Radiology},
issn = {0174-1551},
number = 3,
volume = 35,
place = {United States},
year = {2012},
month = {6}
}